The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.
The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.
Vertebrates express three highly related Myb transcription factors, A-Myb, B-Myb, and c-Myb, which have highly related DNA-binding domains but distinct biological functions (1) . The avian c-myb gene is the proto-oncogene progenitor of the v-myb oncogenes, the transforming components of the avian leukemia viruses avian myeloblastosis virus and E26 (1), both of which induce leukemias in birds and transform immature hematopoietic cells in tissue culture. The human c-myb gene (MYB) is highly expressed in proliferating epithelial, endothelial, and hematopoietic cells as well as pancreatic, colon and breast tumors and most leukemias and lymphomas (2) (3) (4) (5) . The expression of c-myb correlates with proliferation and decreases during differentiation. Deletion of both murine c-myb alleles leads to a failure in definitive hematopoiesis and embryonic lethality (6) , and antisense oligonucleotides targeting c-myb block the proliferation and differentiation of human hematopoietic cells (7) , suggesting that functional c-Myb protein is required for normal hematopoiesis. The c-Myb protein is highly regulated through autoinhibitory mechanisms, protein-protein interactions, and post-translational modifications (8 -11) . The A-Myb gene (MYBL1) is expressed in a subset of the cells that express c-Myb, including specialized, proliferating epithelial cells in the testis and developing mammary gland, as well as many hematopoietic lineages (12) (13) (14) (15) . The B-Myb gene (MYBL2) is involved in S phase transcriptional regulation, is more highly expressed in dividing cells, and is generally a poor prognostic factor in tumors (2, 16 -20) .
The three vertebrate Myb proteins have similar overall structures including nearly identical DNA-binding domains near their N termini, central transcriptional activation domains, and Cterminal negative regulatory domains. All three Myb proteins are DNA-binding transcriptional activators, and all activate the same plasmid-based reporter genes in transfection assays (21) . It was expected that ectopic expression of the three proteins would lead to the activation of similar sets of endogenous genes. However, when recombinant adenovirus vectors were used to express the A-Myb, B-Myb, or c-Myb proteins in MCF-7 mammary cells, each protein stimulated the expression of a distinct set of endogenous genes (22) , suggesting that each protein interacted with unique cofactors or cooperating transcription factors that determined its target gene specificity.
Although the DNA-binding domains of A-Myb, B-Myb, and c-Myb are very closely related, they have some differences that could be important for regulating specific genes (1). Indeed, changing a single amino acid in the DNA-binding domain of avian myeloblastosis virus v-Myb has been shown to affect its ability to activate some endogenous genes (23) . Alternatively, if the differences in the DNA-binding domains were inconsequential, then other parts of the proteins, such as the unique transcriptional activation domains, must be responsible for the different activities. Such a result would imply that relatively small changes in the transcriptional activation domains could lead to dramatic changes in gene expression. That would have important implications for the use of fusion proteins that alter the transcriptional activation domain, such as Myb-estrogen receptor fusion proteins, which are hormone-regulatable and have been used for identifying potential Myb-regulated genes (24 -26) . The transcriptional activation domain of avian myelo-blastosis virus v-Myb contains several point mutations that contribute to its transforming activity (27, 28) . The c-Myb transcriptional activation domain is subject to several types of post-translational modifications (29 -36) . Such changes could cause qualitative differences in the transcriptional activities of the Myb proteins (37) .
Here, the relative importance of differences in the DNAbinding and transcriptional activation domains of Myb proteins was investigated. A series of domain swap and deletion mutants were constructed and compared using reporter gene assays or endogenous gene activation assays in both chicken and human cells. The results have important implications for understanding how the specificities of Myb transcription factors are regulated in different cell types.
EXPERIMENTAL PROCEDURES
Plasmid Construction-Chicken A-Myb and c-Myb cDNAs were cloned in pCDNA3 expression vectors (Invitrogen) and have been described (22) . The domain swaps were constructed by exchanging fragments of A-Myb and c-Myb after digestion with EcoRI and HincII. The AH, AP, AB, and AN deletions of A-Myb and the CH and CN deletions of c-Myb were constructed by digesting the appropriate cDNAs with restriction enzymes HincII, PstI, BglII, or NsiI (H-N, respectively), converted to blunt ends, and ligated into XbaI/T4 DNA polymerasetreated pCDNA3. The in-frame TAG from the XbaI site in the vector formed the stop codon. The AT, CT, and CX deletions were constructed through PCR amplification using the T7 primer 5Ј-TAATACGACTCA-CTATAGGG-3Ј in combination with primers 5Ј-AATCTAGAAATTCT-GCTGAACGGATGTGC-3Ј, 5Ј-ATTCTAGAATAAGCAACCATGATCC-ACTG-3Ј, or 5Ј-ATCTCGAGCATGAAAGGCTGGTCCCTG-3Ј, respectively, using high fidelity polymerase Pfu (Stratagene, La Jolla, CA). The resulting AT and CT products were digested with XbaI, the CX product was digested with XhoI, and then the fragments were cloned into pCDNA3. All the constructs were verified through nucleotide sequencing.
Transfections and Luciferase Assays-Quail fibroblast cells (QT6) were grown and transfected as described previously (8, 10, 38) . Human 293 fibroblasts were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and were transfected using LipofectAMINE (Invitrogen) or FuGENE 6 (Roche Applied Science) as recommended by the manufacturers. All of the results are representative of at least three independent experiments.
Construction of Recombinant Adenoviruses-The cDNAs of chicken A-Myb, c-Myb, or the domain swap or deletion constructs were transferred to the shuttle vector pAdTrack cytomegalovirus and recombined with pAdEasy as described (39) , except that bacteria DY329 was used for more efficient recombination (40) . All the adenovirus vectors were tested through transfection-transduction analysis and Western blotting to ensure that they expressed active Myb proteins of the expected sizes.
Microarray Analyses-Gene expression assays in adenovirus-infected MCF7 cells were performed as described previously. Briefly, sufficient virus was used to yield 100% transduced cells, judged by monitoring the coexpressed green fluorescent protein (39) , and roughly equivalent levels of Myb proteins, judged by Western blotting. After 16 h, total RNA was prepared using RNeasy mini kits (Qiagen). RNA quality was judged using the Lab-on-a-Chip Bioanalyzer 2100 (Agilent, Palo Alto, CA), and then hybridization probes were prepared and hybridized to U95A or U133A GeneChips exactly as described by the manufacturer (Affymetrix, Santa Clara, CA), using the Superscript Choice System (Invitrogen) and the RNA transcript labeling kit (ENZO, Farmingdale, NY) for cRNA preparation. Microarray analysis was performed using the Affymetrix GeneArray Scanner G2500A, and the samples were scaled to a median fluorescence of 500 units using Microarray Suite 5.0 software (Affymetrix). Replicate samples were generated and analyzed on different days.
Affymetrix pivot table data were imported into GeneSpring 5.1 software (Silicon Genetics, Redwood City, CA), and the data were normalized on a per gene basis to the median values of the control samples (uninfected and infected with a control adenovirus). The GeneSpring cross-gene error model was used for all analyses. Filtering was used to identify genes that were expressed above a threshold of 1000 raw units in any Myb-expressing samples and that were also induced or repressed at least 2.5-fold relative to the respective control samples or as described in the text.
Northern and Western Blotting-To detect the transcription of the mim-1 gene, QT6 fibroblast cells were plated into 6-well plates at a density of 3.75 ϫ 10 5 cells/well, 24 h before transfecting with Myb and NF-M expression vectors (38) as described above. After 48 h, the cells were harvested by scraping into cold phosphate-buffered saline, 10% of the cells were used for Western blotting, and the rest were used for RNA extraction, as described above. RNAs (5.0 g) were analyzed in 1% formaldehyde-agarose gels, followed by transfer to Hybond nylon membrane (Amersham Biosciences). The probes were prepared by labeling mim-1 or ␤-actin cDNAs with the Rediprime II random prime labeling system (Amersham Biosciences). The membranes were hybridized multiple times after stripping with 0.1% boiling SDS solution. A similar procedure was used for Northern blots of human cells transduced as described above. The cDNA probes for human genes were isolated through reverse transcriptase-PCR and verified by nucleotide sequencing before use. For Western blots, the proteins were fractionated on 12% SDS-PAGE gels and analyzed using Myb-specific antibodies as described previously (8 -10) . Quantification of Northern blot data was performed using Alpha Imager 2200 software (Alpha Innotech, San Leandro, CA).
RESULTS

A-Myb and c-Myb Have Unique, Context-specific Activities-
The use of recombinant adenovirus vectors provides a flexible and efficient means of expressing various Myb proteins in a variety of human cells in tissue culture. Previously, we employed that strategy to express A-Myb, B-Myb, and c-Myb proteins in human MCF-7 mammary cells (22) , an epithelial cell line that expresses all three Myb proteins during estrogeninduced proliferation (41) . To extend our previous results, we used the same adenovirus-based approach to compare the activities of A-Myb and c-Myb in two additional cell types: primary lung epithelial cells and primary lung fibroblasts. In each case, the adenovirus titers were adjusted to ensure that roughly equivalent levels of A-Myb and c-Myb were expressed and that essentially all of the cells in the culture were infected (as judged by expression of the coexpressed green fluorescent protein). After 16 h, RNA was prepared from uninfected cells or cells infected with control virus (green fluorescent protein only) or with viruses expressing A-Myb or c-Myb, and changes in gene expression were analyzed using Affymetrix U95Av2 GeneChips, containing probe sets for more than 12,000 genes. The data from each cell type were normalized to the respective uninfected or control virus-infected cells. Filtering was used to identify 354 genes that were designated "Present" in at least one sample (using the Affymetrix Microarray Suite software) and that were up-or down-regulated at least 3.5-fold, relative to the controls, in at least one of the experimental conditions. Additional t test filtering identified a subset of 61 genes that were most significant. The results for those 61 genes are summarized in Fig. 1A . The data for the larger set of 354 genes are available as supplementary material.
The gene tree in Fig. 1A summarizes the gene expression changes for the 61 genes that were most significantly up-or down-regulated following A-Myb or c-Myb expression in the three cell types. The figure is color-coded to show genes that were down-regulated (blue), unchanged (white), or up-regulated (red). The analysis identified a number of genes whose expression changed as a result of Myb protein expression. The cell type specificities of the affected genes are summarized in the Venn Diagrams shown in Fig. 1B . Ectopic expression of A-Myb (top panel) led to increased or decreased expression of 132, 13, or 108 genes in MCF-7, lung epithelial, or lung fibroblasts, respectively. However, there were no genes that were strongly affected by A-Myb in all cell types. Similarly, 66, 25, and 119 genes were up-or down-regulated following c-Myb expression in MCF-7, lung epithelial, or lung fibroblast cells, respectively (bottom panel). Only three probe sets were affected in all three cell types. Two of them represented the same gene, RRAD, a ras-related GTPase that was up-regulated in the two lung cell types and down-regulated in MCF-7 cells (Fig. 1C) . The other consistently activated gene was ISG20, an interferon-inducible gene that was up-regulated by c-Myb in all three cell types. Although it is an interferon-inducible gene, ISG20 was not up-regulated in response to the control adenovirus vectors (data not shown), so it appears to respond to expression of c-Myb rather than the adenovirus infection.
The Venn Diagrams in Fig. 1D compare the sets of genes most affected by A-Myb and c-Myb in the three cell types.
), suggesting that they should be able to access the same promoters in the chromatin, they affected different sets of genes in each cell type. We conclude that the different cellular environments confer unique activities on each Myb protein, probably through alternative protein-protein interactions with tissue-specific coactivators or regulatory proteins.
Transactivation Domain Differences in A-Myb and c-MybThe microarray assays showed that the A-Myb and c-Myb proteins affected the expression of different sets of genes. Because the two proteins have some domains that are nearly identical and others that are unique, experiments were designed to map the domains that were responsible for their different transcriptional activities. The A-Myb and c-Myb cDNAs have conserved EcoRI and HincII restriction sites in the regions encoding the DNA-binding and transcriptional activation domains. These sites were used to construct the domain swap mutants diagrammed in Fig. 2A . For example, the AEC and AHC constructs have the N terminus and DNA-binding domain from A-Myb fused to the remainder of c-Myb at the EcoRI or HincII sites, respectively. The reciprocal swaps resulted in the CEA and CHA constructs. All were first tested in a transfection assay utilizing a plasmid reporter gene with a Myb-responsive promoter. As shown in Fig. 2B , all the Myb proteins activated the reporter construct at least 30-fold, showing that all the proteins were able to bind Myb-responsive promoters and activate transcription. Western blot assays confirmed that all the proteins were of the expected size and were expressed at similar levels in the transfected cells (data not shown). In general, the proteins containing the A-Myb transcriptional activation domains were the most active in this assay, suggesting that A-Myb is a stronger activator than cMyb. The exception was the AHC swap construct, which combined the A-Myb DNA-binding domain with the c-Myb transcriptional activation domain and which was the most active in the reporter gene assay. Thus, there was no correlation between specific domains in the Myb proteins and the relative activity in the reporter gene assay.
A Northern blot assay was used to test whether the Myb proteins could activate endogenous Myb-regulated genes. The avian mim-1 gene is a well characterized gene that is regulated through the cooperative action of c-Myb plus NF-M, the avian CCAAT/enhancer-binding protein-␤ protein (38, 42) . Cotransfection of c-Myb plus NF-M results in activation of the endogenous mim-1 gene in a variety of cell types (38) . As shown in Fig. 2C , when the A-Myb, c-Myb, and swap construct expression vectors were cotransfected into avian cells along with an NF-M plasmid, all the proteins containing the c-Myb transcriptional activation domains (c-Myb, AEC, and AHC) were able to activate the mim-1 gene. Minor differences in the c-Myb DNAbinding domain can influence interactions with NF-M and affect activation of the mim-1 gene (23, 38, 42) . However, ex-
FIG. 2. Activities of domain swap mutants.
A, domain swap constructs. The diagrams summarize the structures of the wild type A-Myb (white) and c-Myb (gray) proteins with the conserved DNA binding (black), transcriptional transactivation, and C-terminal negative regulatory domains indicated. The proteins and cDNAs share several areas of sequence identity, including conserved EcoRI (E) and HincII (H) restriction sites that were used to construct the domain swap mutants AEC, AHC, CEA, and CHA. B, reporter assays. Plasmids expressing A-Myb, c-Myb, or the swap constructs were transfected into human 293 fibroblasts along with a Myb-responsive reporter gene (EW5-luc) containing a luciferase reporter gene under the control of a minimal promoter supplemented with five high affinity Myb sites. After 2 days, the luciferase activity was determined as a measure of Myb-dependent gene activation. The error bars indicate the range of duplicate transfection assays performed in parallel. Similar results were obtained in multiple trials and with several different cell lines. C, endogenous gene activation assays. The A-Myb, c-Myb, or swap construct expression vectors were transfected into quail QT6 fibroblast cells along with a plasmid expressing NF-M. After 2 days, RNA was purified and analyzed by Northern blotting for expression of the endogenous mim-1 or ␤-actin genes. Similar results were obtained using the chicken cell line HD-11.
changing the A-Myb and c-Myb DNA-binding domains had no such effect. Interestingly, c-Myb, the weakest activator (30-fold) in the reporter gene assay, and AHC, the strongest activator (600-fold) in the reporter assay, activated expression of the endogenous mim-1 gene to similar levels. Thus, the ability to activate mim-1 expression did not correlate with the activities observed in the reporter gene assays. In the mim-1 gene activation assay, the A-Myb and c-Myb DNA-binding domains were interchangeable, but the C-terminal and transcriptional activation domains determined specificity. We conclude that, at least for some Myb-regulated genes, the differences between A-Myb and c-Myb are defined by differences in their transcriptional activation domains. Those differences are qualitative, rather than quantitative and do not correlate with results obtained with reporter gene assays.
Mapping Specificity Determinants in A-Myb and c-Myb-The results using the mim-1 assay suggested that differences in the transcriptional activation domains between A-Myb and c-Myb determined their ability to activate specific genes. Microarray assays were used to test this hypothesis on additional target genes. Briefly, adenovirus vectors expressing A-Myb, c-Myb, and the swap constructs CHA and AHC were constructed and used to infect human MCF-7 mammary epithelial cells, as described above. After 16 h, RNA was prepared and analyzed using Affymetrix U133A GeneChips, containing probe sets specific for more than 16,000 human genes. The entire experiment was performed in duplicate, and the gene expression data were normalized to samples that were infected with a control (green fluorescent protein only) adenovirus. Filtering was used to identify 45 genes that met one of the following criteria; they were reproducibly up-regulated 2.5-fold or more as a result of expression of either A-Myb or c-Myb, reproducibly up-regulated by c-Myb at least 2-fold more than by A-Myb or vice versa, or expressed above background in the control samples and reproducibly down-regulated at least 2-fold after either A-Myb or c-Myb expression. The gene expression data from 16 representative genes that displayed domain-specific regulation are summarized in Fig. 3A , where unaffected and up-regulated genes are shaded white or red, respectively. The data for five of the genes are also reproduced in bar graph form in Fig. 3B . The activation of these five genes were confirmed in a separate experiment in which changes in gene expression induced by A-Myb, c-Myb, and all the swap constructs were assessed by Northern blotting (Fig. 3C) .
Several genes, such as KRT16 and DHRS2, were strongly activated by A-Myb, c-Myb, and all of the swap constructs. However, other genes showed a dramatic difference in activation following expression of the various Myb proteins. For example, the genes MAD1L1, CD44, DSIPI, EPAS1, and RAB31 were all activated more strongly by A-Myb and the AHC swap construct than by c-Myb or CHA. In the Northern blot experiment shown in Fig. 3C , the DSIPI gene was activated by expression of A-Myb, CEA, and AHC, all of which contain the region of the A-Myb protein bounded by the EcoRI and HincII restriction sites. The c-Myb, AEC, or CHA proteins, lacking that domain, did not activate DSIPI above background levels. These results suggest that, for activation of genes like DSIPI, the A-Myb and c-Myb DNA-binding domains were interchangeable, but the EcoRI to HincII region of A-Myb was required. In contrast, the EPHX1 and ASS1 genes were strongly activated following expression of c-Myb and either the AEC or AHC swap constructs. Again, exchanging the A-Myb and c-Myb DNA-binding domains had no effect, but only proteins containing the c-Myb C-terminal and transcriptional activation domains could activate the EPHX1 and ASS1 genes. Taken together, these results suggest that subdomains in the C-terminal and transcriptional activation domains of c-Myb and A-Myb control their specificity and ability to affect the expression of specific genes.
Positive and Negative Elements Control Specificity-Because the C-terminal domains of c-Myb and A-Myb contained determinants that affected the activation of specific genes, we constructed a series of C-terminal deletion mutants that could be used for more precise mapping (Fig. 4A) . The deletion constructs of c-Myb and A-Myb were transfected into avian QT6 fibroblasts along with a required NF-M expression plasmid. Western blot assays showed that all the proteins were expressed at roughly equivalent levels (data not shown). After 2 days, RNA was prepared and analyzed by Northern blotting to detect the expression of the endogenous mim-1 and ␤-actin genes (as an RNA loading control). As shown in Fig. 4B , the mim-1 gene was not activated by the shortest c-Myb construct, CH, but was activated by CT and all the longer proteins. Thus, the region that distinguishes the CH and CT constructs, residues 304 -365, was required for activation of the endogenous mim-1 gene. The A-Myb deletion mutants revealed more complexities. As with c-Myb, the shortest A-Myb derivative, AH, was unable to activate mim-1 expression, but the slightly longer AT protein activated the gene very efficiently (compare Fig. 4C, lanes 2 and 3) . Thus, residues 282-319 of A-Myb, which distinguish AH from AT, were required for mim-1 gene activation. However, unlike c-Myb, the full-length A-Myb construct was a poor activator of mim-1 (Fig. 4C, lane 1) , although shorter constructs, such as AN, activated the mim-1 gene quite well. Thus, residues 633-757, at the extreme C terminus of A-Myb, had a negative influence on the ability of A-Myb to activate the mim-1 gene. These results suggest that the c-Myb and A-Myb C-terminal domains contain functional subdomains that exert positive or negative effects on the activation of genes like mim-1.
The deletion constructs were also tested for their ability to activate some of the human genes identified through the microarray assays described above. Briefly, recombinant adenoviruses expressing the deletion constructs were used to infect MCF-7 cells. RNA was prepared after 16 h and used for Northern blot analysis, using cDNA probes specific for the genes of interest. The results suggested that several subdomains in the c-Myb and A-Myb proteins affected the expression of specific genes. For example, as shown in Fig. 5 (A and B) , all of the A-Myb constructs (lanes 1-6) , including the shortest protein AH, were able to activate the DHRS2 gene above background levels (lane 7). This differs from the result with the mim-1 gene (above), which could not be activated by the AH construct. However, the AT protein was more active than AH, suggesting that the region distinguishing those two constructs, residues 282-319, had a positive influence on DHRS2 gene activation. The longer A-Myb constructs were all less active, suggesting that residues 319 -410 had a negative effect on DHRS2 activation. In contrast, the DSIPI gene could not be activated above background by the AH protein but was activated in response to expression of all the longer A-Myb constructs, suggesting that residues 282-319 were required for DSIPI activation. The EPHX1 gene was activated by constructs AT and AP but not by shorter or longer proteins, suggesting that residues 282-319 were required for EPHX1 activation but that residues 410 -551 contained a negative regulatory domain that prevented the longer constructs from activating the EPHX1 gene.
The results with c-Myb were similarly complex. As shown in Fig. 5A (lanes 7-13) , all the c-Myb constructs, including the shortest protein CH, activated the DHRS2 gene quite strongly. As mentioned above, this differs from results with the mim-1 gene, which could not be activated by CH. This suggests that residues 200 -304 are the only portion of the transcriptional activation domain of c-Myb that is required for activation of the DHRS2 gene. In contrast, none of the c-Myb proteins were able to activate the DSIPI gene, which was A-Myb-specific. Although full-length c-Myb as well as CT and the longer constructs activated the EPHX1 gene, the shorter CH construct did not, suggesting that residues 304 -365 of c-Myb, the domain required for activation of the mim-1 gene, were also required for activation of EPHX1.
The positive and negative acting domains in A-Myb and c-Myb affecting each target gene are summarized as boxes and lines, respectively, in the diagram in Fig. 5C . The results suggest that A-Myb contains a positive acting region important for the activation of numerous genes located in residues 282-319, as well as several negative acting regions that specifically affect the activation of individual classes of genes. Examples are residues 319 -410, 410 -551, and 633-757 that affect activation of DHRS2, EPHX1, and mim-1, respectively. Similarly, c-Myb contains a positive acting region in residues 200 -304 that is sufficient for activation of DHRS2 and an additional positive acting region in residues 304 -365 that is required for activation of EPHX1 and mim-1. Based on these results, we conclude that the A-Myb and c-Myb transcription factors have unique specificities for activating different genes in both avian and human cells and that their activities are determined by the functions of subdomains within the C-terminal regions that have gene-specific positive or negative effects. One of the most striking conclusions from our data is the almost complete disconnect between the results obtained with reporter gene assays and the results observed by following endogenous target genes. Thus, both A-Myb and c-Myb were able to activate the same reporter genes, but each regulated a different set of endogenous genes, both in chicken and in human cells. Furthermore, the domain swaps that had such dramatic effects on the regulation of endogenous genes had little or no effect on the reporter gene assays. For example, as shown in Fig. 2 , A-Myb and the swap construct AEC, both of which have the A-Myb N terminus and DNA-binding domain, activated the reporter gene more than 50-fold. Although A-Myb was about 2-fold more active in the reporter gene assay, it was unable to activate the endogenous mim-1 gene, which AEC did activate. The same was true for the human genes EPHX1 and ASS1, which AEC activated much more strongly than A-Myb (Fig. 3) . The results of the reporter gene assays cannot be used to predict which proteins are able to activate a particular endogenous gene. The reporter gene assays are not useless, because they can distinguish proteins that have lost DNA binding activity or ones that have gross mutations in their transcriptional activation domains. However, the results suggest that, in terms of identifying biological differences between transcription factors, reporter assays are a poor substitute for assaying changes in the expression of endogenous genes.
Another surprising result was the extreme cell type specificity of the Myb proteins, which could be due to differences in chromatin structure in the different cell types. Thus, different chromatin structures might make different genes accessible in MCF-7 cells than in lung fibroblasts. However, because A-Myb and c-Myb recognize the same DNA sequences, they should be able to access the same promoters in "open" chromatin. Because the two proteins regulated different sets of genes, there must also be other factors influencing specificity that are Myb-specific.
We mapped the ability to activate specific genes to small subdomains within the transcriptional activation domains of c-Myb and A-Myb and showed that the domains confer both positive and negative regulatory affects. It seems likely that the subdomains we identified represent interaction sites for cofactors or coregulators that impart negative or positive influences on A-Myb or c-Myb activity, in a gene-specific manner. These results are somewhat unexpected, because transcriptional activation domains are often exchanged between transcription factors. In our experiments, exchanging the transcriptional activation domains of c-Myb and A-Myb had dramatic effects on the genes that were subsequently affected. This calls into question experiments that use fusion proteins, for example the DNA-binding domain of c-Myb fused to the hormone-binding domain of the estrogen receptor (24 -26, 44) . The wild type and fusion proteins would have to be compared in microarray assays to determine whether they regulate similar or completely different sets of genes.
The transcriptional activation domain of c-Myb is subject to several types of post-translational modifications, including phosphorylation, ubiquitinylation, sumoylation, acetylation, and probably others (30, 33-36, 45, 46) . Our results raise the possibility that slight differences in Myb proteins, for example differences in protein phosphorylation, could change the spectrum of genes that are regulated. Thus, a phosphorylated form of c-Myb could regulate completely different genes than a nonphosphorylated one. In addition, c-myb gene has several alternative exons that could result in proteins with altered transcriptional activation domains. Thus, the c-myb gene may encode a family of related transcription factors that, like the A-Myb and c-Myb proteins we tested, possess unique transcriptional activities that can be further modified by multiple up- stream signaling pathways that induce changes in post-translational modifications (37) . Clearly, the Myb proteins have the potential for inducing many different types of gene expression changes in different situations.
